Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern
Time
HENDERSON, Nev., Nov. 8, 2024
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition") today announces that it will host a conference call on
Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its
financial and operating results for the third quarter 2024, in
addition to providing a business update. Details of this event can
be found below.
Event: VolitionRx Limited Third Quarter 2024 Earnings and
Business Update Conference Call
Date:
Friday, November 15,
2024
Time: 8:30
a.m. U.S. Eastern Time
U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13750104
Louise Batchelor, Group Chief
Marketing & Communications Officer will host the call along
with Cameron Reynolds, President and
Group Chief Executive Officer of Volition, Terig Hughes, Group
Chief Financial Officer, Dr Tom
Butera, Chief Executive Officer of Volition Veterinary
Diagnostics Development LLC and Dr. Andrew
Retter, Chief Medical Officer. The call will provide an
update on important events that have taken place in the third
quarter of 2024 and upcoming milestones.
A live audio webcast of the conference call will also be
available on this link. In addition, a telephone replay of the call
will be available until November 29,
2024. The replay dial-in numbers are 1-844-512-2921
(toll-free) in the U.S. and Canada
and 1-412-317-6671 (toll) internationally. Please use replay pin
number 13750104.
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, disease and treatment
monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is included
in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish,
Volition,
mediarelations@volition.com,
+44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2024-earnings-conference-call-and-business-update-302299871.html
SOURCE VolitionRx Limited